Literature DB >> 14739765

Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system.

Matthias Pauschinger1, Kumaran Chandrasekharan, Heinz-Peter Schultheiss.   

Abstract

Matrix metalloproteinases (MMP), a family of proteases, are involved in the degradation of extracellular matrix proteins and hence in the determination of interstitial architecture. In the heart, MMPs have been found to play a significant role in the development of myocardial remodeling and congestive heart failure. Tissue inhibitors of matrix metalloproteinases (TIMPs) represent a family of proteins which are known to regulate the expression and activity of MMPs. TIMPs are endogenous physiological inhibitors of MMPs and their concomitant downregulation in heart failure suggests the existence of a critical balance between MMPs and TIMPs in the normal maintenance of myocardial interstitial homeostasis. In addition, cytokines regulate expression of both MMPs and TIMPs besides eliciting a direct effect on myocardial cell function. Therefore, myocardial inflammation may also contribute to the development of cardiac remodeling along with other stimuli like mechanical stress and humoral factors. Viral myocarditis, a predisposing factor for dilated cardiomyopathy, is a condition in which extent of intramyocardial inflammation is thought to determine the progression of disease. Inflammatory events in the heart following viral infection are speculated to be responsible for the transition of myocarditis to dilated cardiomyopathy. In viral myocarditis and other inflammatory heart diseases, the inflammatory cells and their battery of cytokines may also alter the myocardial MMP-TIMP system and eventually lead to dilation of the heart and ventricular dysfunction. The objective of this review is to present an overall picture of the inflammatory phase in viral myocarditis and discuss the possible interactions between inflammation and myocardial MMP profiles which may lead to the evolution of dilated cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14739765     DOI: 10.1023/B:HREV.0000011391.81676.3c

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  120 in total

1.  Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results.

Authors:  R Wojnicz; E Nowalany-Kozielska; C Wojciechowska; G Glanowska; P Wilczewski; T Niklewski; M Zembala; L Polonski; M M Rozek; J Wodniecki
Journal:  Circulation       Date:  2001-07-03       Impact factor: 29.690

2.  Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors.

Authors:  G Velasco; S Cal; A Merlos-Suárez; A A Ferrando; S Alvarez; A Nakano; J Arribas; C López-Otín
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

Review 3.  Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases.

Authors:  P Borden; R A Heller
Journal:  Crit Rev Eukaryot Gene Expr       Date:  1997       Impact factor: 1.807

Review 4.  Relating matrix metalloproteinase structure to function: why the "hemopexin" domain?

Authors:  G Murphy; V Knäuper
Journal:  Matrix Biol       Date:  1997-03       Impact factor: 11.583

5.  Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells.

Authors:  W C Duivenvoorden; H W Hirte; G Singh
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

6.  Human membrane type-4 matrix metalloproteinase (MT4-MMP) is encoded by a novel major transcript: isolation of complementary DNA clones for human and mouse mt4-mmp transcripts.

Authors:  M Kajita; H Kinoh; N Ito; A Takamura; Y Itoh; A Okada; H Sato; M Seiki
Journal:  FEBS Lett       Date:  1999-09-03       Impact factor: 4.124

Review 7.  Molecular approaches to enteroviral diagnosis in idiopathic cardiomyopathy and myocarditis.

Authors:  S Tracy; V Wiegand; B McManus; C Gauntt; M Pallansch; M Beck; N Chapman
Journal:  J Am Coll Cardiol       Date:  1990-06       Impact factor: 24.094

8.  Acute myocarditis. Rapid diagnosis by PCR in children.

Authors:  A B Martin; S Webber; F J Fricker; R Jaffe; G Demmler; D Kearney; Y H Zhang; J Bodurtha; B Gelb; J Ni
Journal:  Circulation       Date:  1994-07       Impact factor: 29.690

9.  Interleukin 4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes.

Authors:  M L Corcoran; W G Stetler-Stevenson; P D Brown; L M Wahl
Journal:  J Biol Chem       Date:  1992-01-05       Impact factor: 5.157

Review 10.  Inflammatory mediators and the failing heart: a translational approach.

Authors:  Abhinav Diwan; Tony Tran; Arunima Misra; Douglas L Mann
Journal:  Curr Mol Med       Date:  2003-03       Impact factor: 2.222

View more
  17 in total

Review 1.  Molecular determinants of the cardiometabolic phenotype.

Authors:  Lisa de las Fuentes; Giovanni de Simone; Donna K Arnett; Víctor G Dávila-Román
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2010-06       Impact factor: 2.895

Review 2.  Targeting matrix metalloproteinase activity and expression for the treatment of viral myocarditis.

Authors:  Reid G Hendry; Leanne M Bilawchuk; David J Marchant
Journal:  J Cardiovasc Transl Res       Date:  2014-01-01       Impact factor: 4.132

Review 3.  The role of the proteasome in heart disease.

Authors:  Yi-Fan Li; Xuejun Wang
Journal:  Biochim Biophys Acta       Date:  2010-09-15

4.  Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice.

Authors:  Stephane Heymans; Florea Lupu; Sven Terclavers; Bjorn Vanwetswinkel; Jean-Marc Herbert; Andrew Baker; Desire Collen; Peter Carmeliet; Lieve Moons
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

Review 5.  Inflammation, ECG changes and pericardial effusion: whom to biopsy in suspected myocarditis?

Authors:  M Pauschinger; M Noutsias; D Lassner; H-P Schultheiss; U Kuehl
Journal:  Clin Res Cardiol       Date:  2006-08-16       Impact factor: 5.460

6.  Antimicrobial agents for myocarditis: target the pathway, not the pathogen.

Authors:  Lori A Blauwet; Leslie T Cooper
Journal:  Heart       Date:  2009-07-16       Impact factor: 5.994

7.  Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species.

Authors:  Tracy L Deem; Joan M Cook-Mills
Journal:  Blood       Date:  2004-07-20       Impact factor: 22.113

8.  Effect of prostaglandin analogs: Latanoprost, bimatoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human trabecular meshwork endothelial cells.

Authors:  Jae Young Heo; Yen Hoong Ooi; Douglas J Rhee
Journal:  Exp Eye Res       Date:  2020-03-25       Impact factor: 3.467

Review 9.  Viral myocarditis: diagnosis, aetiology and management.

Authors:  Uwe Kühl; Heinz-Peter Schultheiss
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

10.  Amelioration of coxsackievirus B3-mediated myocarditis by inhibition of tissue inhibitors of matrix metalloproteinase-1.

Authors:  Stephen J Crocker; Ricardo F Frausto; Jason K Whitmire; Nicola Benning; Richard Milner; J Lindsay Whitton
Journal:  Am J Pathol       Date:  2007-11-30       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.